Vaksin China tidak selamat
Chinese state pushes back against widespread outrage
over vaccine crisis
(CNN)The Chinese government is
turning to censorship and appeals for calm, amid mounting public anger
following revelations earlier this week that one of the country's largest
vaccine makers had violated safety standards.
Furor about the faulty vaccines, an estimated 250,000 of which
may have been administrated to children, has continued to dominate Chinese
social media, further eroding public trust in essential services.
There are also suggestions the scandal could affect China's
standing overseas as the country tries to position itself as a major player in
the global pharmaceutical industry.
On Tuesday, the chairperson of the company at the center of the
scandal, Gao Junfang of Changchun Changsheng Biotechnology, was detained, along
with 14 other people involved in the case, according to an official police
statement.
The swift actions of the police have so far done little to quell
the outcry. Outside the Capital Institute of Pediatrics in Beijing, one of the
country's premier children's hospitals, one parent told CNN the company had
"no conscience" and the government needed to regulate more strictly.
Another parent, Peng Yubin, said he was considering using
foreign vaccines for his child. "Even though they are more expensive, they
are better," he said.
Several days on from the initial news, there is still no
official information regarding how many children may have been injected with
the questionable vaccines or what effect they may have.
In an article published Tuesday, state-owned China Daily quoted
experts calling for "a rational attitude" towards immunization,
saying the faulty diphtheria and tetanus vaccines (DPT) "won't harm
people's health." Similarly, the official newspaper of the Communist
Party, the People's Daily, ran an interview with an expert alleging the vaccines were "safe," just ineffective. Evidence in support of these claims has
yet to be provided by authorities.
On Monday evening, State Drug Administration Deputy Director Xu
Jinghe appeared on state-owned CCTV in an attempt to calm public concerns, but
the footage provoked scorn, with social media users mocking Xu's expensive,
blue Burberry polo shirt and stilted answers.
One Weibo user reprimanded Xu for his choice of clothes:
"Improper dressing for such an occasion." "The people are fed up
with you!" another user posted.
Government censors had initially allowed public discussion.
However, by Wednesday, attempts were underway to control the flow of
information, with the word "vaccine" among the most restricted on
China's social media platform Weibo, according to the Journalism and Media
Studies Centre at the University of Hong Kong.
Numerous essays and top rated comments were scrubbed from online
platforms, including a widely shared article titled "King of
Vaccine," which accused the owner of Changsheng of corruption and
unethical behavior.
International ramifications?
There is growing evidence the scandal could spill beyond China's
borders, impacting the country's long held ambition to become a major player in
the global pharmaceutical industry.
"The Changchun Changsheng scandal jeopardizes Beijing's
efforts to push domestically made pharmaceuticals on the international
market," wrote Viola Rothschild, a research associate in Asia Studies at
the Council on Foreign Relations, in a blog posted Tuesday.
"Under China's 'Made in China 2025' plan, pharmaceuticals
are a target industry: President Xi has identified China's reliance on imported
drugs as an issue that can be resolved by overhauling the pharmaceutical
industry and ultimately creating globally competitive firms," said
Rothschild.
In Changchun Changsheng's 2017 annual report, which it filed to
the Shenzhen Stock Exchange, the company claimed to have sold products to "more than ten countries like India, Cambodia,
Nigeria, Egypt, Belarus and some other European, African, Middle Eastern and
South American countries."
According to the report, Changchun Changsheng sold more than 36
million yuan ($5.28 million) worth of goods overseas in 2017.
There is no indication that the defected vaccines were among
those shipped to other countries. CNN has contacted health ministries of the
countries listed in the annual report for comment.
"Chinese manufacturers (across all sectors) have worked
hard to shake the conception that 'Made in China' is synonymous with 'low
quality,' but incidents like these undermine trust and are a reminder that
despite recent reforms and advancements, safety and testing requirements in
China are not up to international standards," said Rothschild.
Chinese Ministry of Foreign Affairs spokesman Geng Shuang said
questions about tainted vaccines being shipped internationally were not a
matter for his ministry at his daily briefing on Tuesday.
Hundreds of thousands potentially affected
The crisis began when more than 250,000 doses of Changchun
Changsheng's diphtheria and tetanus (DPT) vaccine were found to be faulty,
according to the Jilin Provincial Food and Drug Administration.
The vaccine is part of the national mandatory program and an
unconfirmed number of children have been given the questionable drugs,
authorities said, provoking widespread outrage and concern.
Another 113,000 doses of Changsheng's rabies vaccine were also
affected, according to authorities.
The controversy is just the latest in a series of public
scandals around Chinese goods and medicines.
In 2008, baby formula produced and fed to infants in China was
discovered to be tainted with melamine, a chemical compound mainly for industrial use, affecting
tens of thousands of children and provoking widespread panic.
Anxious parents emptied supermarket shelves in Hong Kong,
Australia and New Zealand, among other places, in their search for safe milk
formula for their infants.
It isn't even the first vaccine scandal China has faced -- in
2016, a criminal organization was found to be selling millions of improperly stored vaccines, which had been widely disseminated.
.
No comments:
Post a Comment
Note: only a member of this blog may post a comment.